Cipla launches generic nintedanib for idiopathic pulmonary fibrosis in India

Cipla launches generic nintedanib for idiopathic pulmonary fibrosis in India

Drug firm Cipla has launched a generic version of the nintedanib drug used for the treatment of Idiopathic pulmonary fibrosis (IPF) under the brand name Nintib in India.

The capsules will be available at doses 100 mg and 150 mg, said the company in a statement. Cipla’s Nintib is priced at Rs 69 (100 mg) and Rs 85 (150 mg) per capsule.

IPF is a chronic progressive form of lung disease with an average survival rate of three to five years if left untreated. It is characterised by scarring in the lungs, wherein the lung tissue becomes stiff and thick.

Nintedanib is approved by the Indian drug regulator for the treatment of IPF. In India, IPF has reportedly been found to affect men over the age of 65. Patients with IPF may also be at higher risk of developing severe respiratory conditions if affected by COVID-19.

Nintedanib was recently approved by the Indian drug regulator for the treatment of IPF. A generic version of nintedanib capsules was also recently launched by the Glenmark Pharmaceuticals under the brand name Nindanib for the treatment of IPF in India.